Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Meningioma 1Breast Neoplasms 1

Interventions

Specimen Handling 278Magnetic Resonance Spectroscopy 233pembrolizumab 227Carboplatin 187Cisplatin 153Biopsy 148Cyclophosphamide 143Paclitaxel 133Nivolumab 122Gemcitabine 113Bevacizumab 104Radiotherapy 92Dexamethasone 86Pemetrexed 83fludarabine 77Fluorouracil 76Docetaxel 75Doxorubicin 74atezolizumab 71Radiation 71Leucovorin 70Rituximab 67Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 60Vincristine 56Cetuximab 56Lenalidomide 54Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Ga(III)-DOTATOC × 30 days × Clear all
NCT04529044 2026-06-05

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
10 enrolled
Breast

Breast Neoplasms

NCT05691465 2026-05-27

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT07150806 2026-05-22

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
30 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡